Photo by Glsun Mall on Unsplash
Roche Enters Obesity Market Through Carmot Therapeutics Acquisition
December 6, 2023
Swiss pharma company Roche recently announced a strategic $2.7 billion deal to acquire U.S.-based Carmot Therapeutics, indicating its entry into the obesity market.
Roche will pay the sum in cash upon closing and may provide further milestone payments of up to $400 million to equity holders. The acquisition allows Roche access to the obesity sector and Carmot’s unique portfolio of incretins: CT-388, CT-996, and CT-868. These incretins are under various stages of research for obesity treatment for patients with or without type 2 diabetes. The portfolio might extend to include conditions such as cardiovascular, retinal, and neurodegenerative diseases.
In addition to Carmot’s incretin portfolio, Roche will secure exclusive access to its novel Chemotype Evolution discovery platform, bolstering its research and development efforts in cardiovascular and metabolic diseases. Despite the promising acquisition, Roche’s shares have declined by 12.2% YTD, contrasting with the industry’s 4.8% growth.
The obesity market has lately been a hotbed of interest, fueling drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro (tirzepatide), among others. Wegovy has seen remarkable demand on the global stage, bolstering Novo Nordisk. On the other hand, Mounjaro, approved in 2022, improves glycemic control in adults with type 2 diabetes when combined with diet and exercise. The FDA recently approved tirzepatide, branded as Zepbound, for adults struggling with obesity or overweight issues, alongside weight-related health conditions like hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease.
However, the obesity market isn’t without its challenges. Pfizer recently experienced a disappointment after its weight loss pill, danuglipron, exhibited side effects in its phase III studies. Despite significant reductions in body weight, the study recorded high rates of gastrointestinal side effects, resulting in high discontinuation rates and the consequent decision by Pfizer not to progress with danuglipron.
Recent News
Massive Data Breach Hits Ticketmaster, Affecting 560 Million Customers
Ticketmaster has fallen victim to a significant cyber-attack, potentially compromising the data of up to 560 million customers. The breach was confirmed by Ticketmaster’s parent company, Live Nation, which revealed that a notorious hacking group, ShinyHunters, is behind the attack. The hackers are demanding a ransom of approximately £400,000 to prevent the data from being sold on the dark web.
Toyota Recalls 100,000+ Tundra and Lexus LX SUVs Over Engine Debris Issue
Toyota has announced a recall for over 100,000 Tundra pickups and Lexus LX SUVs in North America due to potential engine issues caused by machining debris. This recall affects certain 2022-2023 models of the Tundra and LX, which are equipped with the new V6 twin-turbo engine. The V6 twin-turbo engine has faced considerable scrutiny regarding its reliability, especially when compared to the previous naturally aspirated V8 engines.
Wordle and Worldle Battle Over Names
A legal dispute has erupted between the wildly popular word game Wordle and the lesser-known geography game Worldle, centering on the similarity of their names. Wordle, which was developed by Josh Wardle in 2021 and later acquired by the New York Times in 2022 for a substantial sum, has gained immense popularity. In this game, players have six attempts to guess a five-letter word.
FDA Issues Recall for Crecelac Goat Milk Infant Formula
The U.S. Food and Drug Administration (FDA) has issued a safety alert regarding Crecelac Goat Milk Infant Formula and other infant formula products imported and distributed by Dairy Manufacturers Inc. The alert highlights Cronobacter contamination concerns with Crecelac Infant Powdered Goat Milk Infant Formula. Although Dairy Manufacturers Inc. initiated a recall on May 24, 2024, due to non-compliance with FDA regulations, new findings of Cronobacter contamination have prompted further action.